The Effect of Endurance Training in Patients With Prostate Cancer

This study has been completed.
Sponsor:
Collaborator:
Herlev Hospital
Information provided by (Responsible Party):
Inge Holm, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT01584960
First received: April 24, 2012
Last updated: November 29, 2013
Last verified: November 2013

April 24, 2012
November 29, 2013
April 2008
May 2012   (final data collection date for primary outcome measure)
PSA doubling time [ Time Frame: 2 years ] [ Designated as safety issue: No ]
PSA dobling time [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01584960 on ClinicalTrials.gov Archive Site
Insulin sensitivity, body composition and inflammation status [ Time Frame: 0 months, 6 months and 24 months of training ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
The Effect of Endurance Training in Patients With Prostate Cancer
The Effect of Endurance Training on PSA Doubling Time, Body Composition, Insulin Sensitivity and Inflammation in Patients With Prostate Cancer

The aim of the present study is to investigate the effect of endurance on PSA doubling time in prostate cancer patients with an elevation in PSA following radical prostatectomy for localized cancer. Furthermore, underlying mechanisms such as reduction in inflammatory markers and improvement in insulin sensitivity and body composition are investigated.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Supportive Care
  • Prostate Cancer
  • Insulin Sensitivity
  • Body Composition, Beneficial
Behavioral: endurance training
2 years of home-based endurance training
Experimental: Prostate cancer, endurance training
Prostate cancer patients doing 2 years of home-based endurance training Cross over design with a control group with no intervention
Intervention: Behavioral: endurance training
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Prostate cancer patients with an increase in PSA following radical prostatectomy

Exclusion Criteria:

  • severe cardiovascular disease
  • severe arthritis
  • severe neuropathy
  • severe hypertension
  • therapy with antidiabetic agents
  • other treatment for prostate cancer than radical prostatectomy
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT01584960
H-D-2008-015
Yes
Inge Holm, Rigshospitalet, Denmark
Inge Holm
Herlev Hospital
Study Director: Bente K Pedersen Centre of Inflammation and Metabolism, Rigshospitalet
Rigshospitalet, Denmark
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP